197 related articles for article (PubMed ID: 21536234)
21. Discovery of the Philadelphia chromosome: a personal perspective.
Nowell PC
J Clin Invest; 2007 Aug; 117(8):2033-5. PubMed ID: 17671636
[TBL] [Abstract][Full Text] [Related]
22. Is b3a2 a better prognostic variant in childhood chronic myeloid leukemia?
Malhotra KP; Sharma CB; Jain J; Grover RK
J Postgrad Med; 2010; 56(3):221-2. PubMed ID: 20739774
[No Abstract] [Full Text] [Related]
23. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
24. Sequential transient novel chromosomal translocations in a patient with chronic myelogenous leukemia in complete cytogenetic remission after therapy with imatinib mesylate.
Papaioannou G; Athanasiadou A; Voutiadou G; Gaitatzi M; Batsis I; Touloumenidou T; Anagnostopoulos A
Cancer Genet; 2011 Dec; 204(12):692-3. PubMed ID: 22285023
[No Abstract] [Full Text] [Related]
25. Improving the management of chronic myeloid leukaemia.
Neylon A; O'Brien S
Hosp Med; 2001 Sep; 62(9):553-5. PubMed ID: 11584615
[TBL] [Abstract][Full Text] [Related]
26. Targeted chronic myeloid leukemia therapy: seeking a cure.
Fausel C
J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):8-12. PubMed ID: 17970609
[TBL] [Abstract][Full Text] [Related]
27. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Qiu JY; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):23-6. PubMed ID: 15946504
[TBL] [Abstract][Full Text] [Related]
28. Treatment for chronic myelogenous leukemia: the long road to imatinib.
Hunter T
J Clin Invest; 2007 Aug; 117(8):2036-43. PubMed ID: 17671637
[TBL] [Abstract][Full Text] [Related]
29. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
Wang L; Pearson K; Pillitteri L; Ferguson JE; Clark RE
Br J Haematol; 2002 Sep; 118(3):771-7. PubMed ID: 12181044
[TBL] [Abstract][Full Text] [Related]
30. Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era.
Mughal TI; Goldman JM
Front Biosci; 2006 Jan; 11():209-20. PubMed ID: 16146726
[TBL] [Abstract][Full Text] [Related]
31. Philadelphia chromosome mosaicism at diagnosis in chronic myeloid leukemia: clinical correlates and effect on imatinib mesylate treatment outcome.
Landstrom AP; Knudson RA; Dewald GW; Ketterling RP; Tefferi A
Leuk Lymphoma; 2007 Nov; 48(11):2137-40. PubMed ID: 17926177
[TBL] [Abstract][Full Text] [Related]
32. First-line therapy for CML: nilotinib comes of age.
Davies J
Lancet Oncol; 2011 Sep; 12(9):826-7. PubMed ID: 21856227
[No Abstract] [Full Text] [Related]
33. [Chronic myeloid leukemia and tyrosine kinase inhibitors].
Mahon FX
Rev Med Interne; 2001 Sep; 22(9):894-9. PubMed ID: 11599196
[TBL] [Abstract][Full Text] [Related]
34. Imatinib (Gleevec) as a paradigm of targeted cancer therapies.
Druker B
Keio J Med; 2010; 59(1):1-3. PubMed ID: 20375651
[No Abstract] [Full Text] [Related]
35. Brian Druker and Charles Sawyers receive the 2011 ASCI/Stanley J. Korsmeyer Award.
Claiborn K
J Clin Invest; 2011 Apr; 121(4):1227-8. PubMed ID: 21630503
[No Abstract] [Full Text] [Related]
36. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia.
Donato NJ; Wu JY; Stapley J; Lin H; Arlinghaus R; Aggarwal BB; Shishodia S; Albitar M; Hayes K; Kantarjian H; Talpaz M
Cancer Res; 2004 Jan; 64(2):672-7. PubMed ID: 14744784
[TBL] [Abstract][Full Text] [Related]
37. Chronic myelogenous leukemia.
Mauro MJ; Druker BJ
Curr Opin Oncol; 2001 Jan; 13(1):3-7. PubMed ID: 11148678
[TBL] [Abstract][Full Text] [Related]
38. Chronic myeloid leukemia with hyperdiploidy: a case report with review of literature.
Belurkar S; Manohar C; Kurien A
Indian J Med Sci; 2013; 67(7-8):188-92. PubMed ID: 24469564
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous regression of Philadelphia chromosome and multiple nonrecurrent clonal chromosomal abnormalities with imatinib mesylate in a patient autografted 22 years before for chronic myelogenous leukemia.
Van Den Akker J; Coppo P; Portnoï MF; Barbu V; Bories D; Gorin NC
Leuk Lymphoma; 2007 Sep; 48(9):1858-65. PubMed ID: 17786726
[TBL] [Abstract][Full Text] [Related]
40. Complete cytogenietic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation.
Koca E; Cetiner D; Goker H; Aksu S; Ozcebe OI; Haznedaroglu IC; Turgan C
Clin Nephrol; 2005 Oct; 64(4):324-6. PubMed ID: 16240908
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
